|
Mutation Information
|
Mutation Site
|
Q148K |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
IN |
|
Combined Mutation
|
in.Q148K+in.S147G+in.G140S+in.L74M |
|
Genotype/Subtype
|
B |
|
Viral Reference
|
AF324493.2;
AF096341.1 |
|
Relevant Drug
|
cabotegravir (CAB);elvitegravir (EVG);raltegravir (RAL);bictegravir (BIC) |
|
Country
|
Canada |
Literature Information
|
PubMed PMID
|
30119633
|
|
Disease
|
HIV infection/AIDS
|
|
Published Year
|
2018 |
|
Journal
|
Retrovirology |
|
Title
|
Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir. |
|
Author
|
Oliveira M,Ibanescu RI,Anstett K,Mésplède T,Routy JP,Robbins MA,Brenner BG,Montreal Primary HIV (PHI) Cohort Study Group. |
|
Evidence
|
In contrast, the respective first appearance of R263K or S153F mutations by 96USSN20 and 5326 viral strains with CAB at weeks 8, was followed by the serial accumulation of mutations along the Q148K/R resistance pathway leading to viral escape by week 48 (Fig. 1).
|
|
|
HIV Mutation Detail Information